# Andson Biotech

**Source:** https://geo.sig.ai/brands/andson-biotech  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Emerging  
**Website:** andsonbiotech.com  
**Last Updated:** 2026-04-14

## Summary

Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.

## Company Overview

Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.

Andson's DynaCHIP system addresses a bottleneck in biopharma quality control and research: traditional mass spectrometry sample preparation for protein analysis (proteomics, antibody characterization, process analytical technology) is labor-intensive and time-consuming — analysts spend hours manually preparing samples for each analysis run. DynaCHIP automates and miniaturizes the sample preparation process, enabling higher throughput while reducing sample volume requirements. The DynaMARK data science layer processes the resulting mass spectrometry data with AI-powered pattern recognition that speeds interpretation of complex protein spectra.

In 2025, Andson Biotech competes in the biopharma analytical instrumentation and laboratory automation market with Waters Corporation (NASDAQ: WAT, the mass spectrometry and chromatography leader), Thermo Fisher Scientific (NASDAQ: TMO, mass spectrometry), and Bruker (NASDAQ: BRKR) for biopharma analytical instrument sales and service. The biopharma manufacturing market is driven by the growth of biologic drugs (monoclonal antibodies, cell and gene therapies) that require sophisticated protein characterization — mass spectrometry is the gold standard for understanding protein structure, identity, and purity. Merck Digital Sciences Studio's investment provides pharmaceutical industry customer access and validation. NIH funding provides academic research customer credibility. The 2025 strategy focuses on biopharma quality control and process analytical technology (PAT) applications, growing pharma manufacturing customer installations, and deepening the data science automation that reduces analyst time per sample.

## Frequently Asked Questions

### What is Andson Biotech?
Andson Biotech is an Atlanta-based biotech company founded in 2020 specializing in cutting-edge mass spectrometry solutions for biopharma and biomanufacturing. The company is a Y Combinator Winter 2022 graduate with $9.1M in total funding and $1.8M in revenue as of December 2024.

### What products and services does Andson Biotech offer?
Andson Biotech offers the DynaCHIP hardware system that delivers productivity gains up to 100x and the DynaMARK data science module that generates on-demand measurements for modern biopharma workflows. These mass spectrometry solutions are designed to enhance productivity for biotech and pharmaceutical manufacturers.

### Who are Andson Biotech's target customers?
Andson Biotech serves biotech and pharmaceutical manufacturers in the biopharma and biomanufacturing sectors. The company has demonstrated strong enterprise traction with these customers.

### When was Andson Biotech founded?
Andson Biotech was founded in 2020. The company participated in Y Combinator's Winter 2022 batch.

### Where is Andson Biotech located?
Andson Biotech is based in Atlanta, Georgia.

### How much funding has Andson Biotech raised?
Andson Biotech has raised $9.1M in total funding over 4 rounds, including a $3.6M seed round in April 2024 and a $5M Series A in October 2025. Investors include Y Combinator, Merck Digital Sciences Studio, BioTools Innovator, National Institutes of Health, and additional investors.

### What are Andson Biotech's key achievements and metrics?
As of December 2024, Andson Biotech achieved $1.8M in revenue with a 12-person team. The company has demonstrated significant funding validation from multiple institutional investors and shows a strong revenue growth trajectory.

### What technology does Andson Biotech use?
Andson Biotech's platform is built on mass spectrometry technology, featuring the DynaCHIP hardware system that delivers up to 100x productivity gains. The DynaMARK data science module provides on-demand measurements tailored for modern biopharma workflows.

### How can I get started with Andson Biotech?
Specific contact information is not provided in the available information. The company is based in Atlanta, GA and serves biotech and pharmaceutical manufacturers.

### What are Andson Biotech's recent developments?
Andson Biotech recently closed a $5M Series A funding round in October 2025, bringing total funding to $9.1M. As of December 2024, the company reported $1.8M in revenue with a team of 12 employees.

## Tags

healthtech, b2b, north-america

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*